Trials / Completed
CompletedNCT03908307
Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China
A 12-month, Open-label, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® Implant 700 µg (Dexamethasone) on Patients With Macular Edema Secondary to Retinal Vein Occlusion in China (YANGTZE Study)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will take place in China to evaluate the safety and efficacy of OZURDEX implant 700 μg in the treatment of macular edema due to retinal vein occlusion (RVO) in patients who have never received treatment for RVO.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OZURDEX | Implant 700 μg |
Timeline
- Start date
- 2019-07-25
- Primary completion
- 2021-09-26
- Completion
- 2021-09-26
- First posted
- 2019-04-09
- Last updated
- 2023-03-31
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03908307. Inclusion in this directory is not an endorsement.